USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: LUMIGEN, INC.
City: SOUTHFIELD
State: MI
Zip+4: 48034 0430
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: (248) 351-5600

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $545,696.00 7
SBIR Phase II $2,218,520.00 3

Award List:

Ultrasensitive Chemiluminescent Enzyme-Linked Assays

Award Year / Program / Phase: 1994 / SBIR / Phase I
Agency: HHS
Principal Investigator: Hashem Akhavan-Tafti
Award Amount: $74,501.00

Ultrasensitive Chemiluminescent Enzyme-Linked Assays

Award Year / Program / Phase: 1995 / SBIR / Phase II
Agency: HHS
Principal Investigator: Hashem Akhavan-Tafti
Award Amount: $749,680.00
Abstract:
Our objective is to prove feasibility of ultrasensitive chemiluminescent assays for the 21 aminoacid polypeptide from HIV gp 120 by Western blotting and cystic fibrosis transmembrane regulator geneby Southern blotting. We have developed a proprietary enzyme-label chemiluminescent detection… More

NOVEL CHEMILUMINESCENT DETECTION OF GENE REARRANGEMENTS

Award Year / Program / Phase: 1997 / SBIR / Phase I
Agency: HHS
Principal Investigator: Akhavan-tafti, hashem
Award Amount: $100,000.00
Abstract:
The objective of Phase I is to develop simple, sensitive and unambiguous chemiluminescent detection of juxtaposed genes in chromosomal translocations associated with many cancers. We propose chemiluminescent assay formats based on simultaneous probing and detection of both genes of a translocation… More

MULTIPLEX CHEMILUMINESCENT DNA SEQUENCING

Award Year / Program / Phase: 1998 / SBIR / Phase I
Agency: HHS
Principal Investigator: Akhavan-tafti, Hashem
Award Amount: $75,017.00

Molecular Diagnostic Assays for Genetic Disease

Award Year / Program / Phase: 2001 / SBIR / Phase I
Agency: HHS
Principal Investigator: Hashem Akhavantafti
Award Amount: $96,178.00
Abstract:
DESCRIPTION (Applicant's Abstract): The objective of Phase 1 is to develop a sensitive test and kit for detection of the Factor V Leiden mutation in human blood using a new nucleic acid ligation-based technology invented at Lumigen. The ligation technology is based on the… More

CHEMILUMINESCENT LABELING AND DETECTION IN GELS

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Hashem Akhavantafti
Award Amount: $100,000.00
Abstract:
The objective of Phase I is to prepare a new family of chemiluminescent label compounds which can be conjugated to proteins and nucleic acids, subjected to electrophoresis and triggered to generate chemiluminescence in the gel. Successful development of the labeling compounds will permit the… More

Molecular Diagnostic Assays for Genetic Diseases

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Hashem Akhavantafti
Award Amount: $0.00
Abstract:
DESCRIPTION (provided by applicant): Phase I of this proposal proved the feasibility of detection of the factor V Leiden mutation in human blood and correct determination of sample genotype as compared to a reference PCR method. The protocol used a new nucleic acid ligation-based technology, LMO… More

Molecular Diagnostic Assays for Genetic Diseases

Award Year / Program / Phase: 2003 / SBIR / Phase II
Agency: HHS
Principal Investigator: Hashem Akhavantafti
Award Amount: $737,428.00
Abstract:
DESCRIPTION (provided by applicant): Phase I of this proposal proved the feasibility of detection of the factor V Leiden mutation in human blood and correct determination of sample genotype as compared to a reference PCR method. The protocol used a new nucleic acid ligation-based technology, LMO… More

Materials for Isolation of Nucleic Acids from Whole Blood without a Lysis Step

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Hashem Akhavantafti
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): The objective of the proposed study is to develop new materials for the rapid isolation of nucleic acids from complex matrices such as whole blood. In Phase I we will prepare functionalized \microparticles for binding and releasing nucleic acids that utilize… More

Materials for Isolation of Nucleic Acids from Whole Blood without a Lysis Step

Award Year / Program / Phase: 2006 / SBIR / Phase II
Agency: HHS
Principal Investigator: Hashem Akhavantafti
Award Amount: $731,412.00
Abstract:
DESCRIPTION (provided by applicant): This Phase II project continues the development and application of new materials, especially magnetic microparticles for directly isolating DNA from cells, tissues, and biological fluids, including whole blood, in an extremely rapid format. The materials… More